Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Pre-Exposure Prophylaxis for Prevention of HIV

Tuesday, May 20, 2014, at 1 p.m. – 2 p.m.

Photo: Two couples; one with two men, another with a man and a woman

An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up. When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.

This session of Grand Rounds will explore the opportunities for using PrEP as another tool to prevent the transmission of HIV and discuss the challenges to effective implementation that must be addressed to make PrEP a success.

Presentation

Beyond the Data Beyond brings you "take home" messages for you to use in your practice, in your classroom and in your home.

Dr. John Iskander sits down with Dr. Dawn Smith and Dr. Melanie Thompson to discuss Pre-Exposure Prophylaxis (PrEP) as an HIV prevention tool. When taken consistently, PrEP has been shown to reduce the risk of HIV infection by up to 92%.

Patients should know that

  • PrEP is very well tolerated
  • No serious side effects were observed and
  • When taken as directed, PrEP is effective

Practitioners should be aware that

  • PrEP is approved for use in populations with substantial risk of ongoing exposure
  • Several resources are available to aid in learning about and prescribing PrEP and
  • Talking to patients about medication adherence and risk reduction is key to efficacy

 

Presented By

Walid Heneine, PhD 
Surveillance, Antiretroviral Prophylaxis and Drug Resistance Team Lead
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
“HIV Pre-exposure Prophylaxis (PrEP) Preclinical Research in Animal Models”

Melanie Thompson, MD
Founder and Principal Investigator
AIDS Research Consortium of Atlanta
“Evolving Evidence from Clinical Trials of HIV Pre-Exposure Prophylaxis”

Dawn Smith, MD, MS, MPH 
Biomedical Interventions Activity Lead, Prevention with Negatives Team
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
“Program and Policy Challenges for Delivery of PrEP”

Facilitated By

John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds

Additional Resources

Get Email Updates

To receive email updates about this page, enter your email address:

Enter Email Address What's this? Submit

Related Links

  • Page last reviewed: April 24, 2014
  • Page last updated: April 24, 2014
  • Content source:
TOP